Health Information Announces Investment from MVM Life Science Partners

Health Information, the dominant provider of point of dispensing messaging in the UK, announces that it has secured a first round of funding from MVM Life Sciences LLP (“MVM”). MVM is a leading EU/US life science venture capital fund with $500m under management. This financing will support the continued development of the company’s pharmacy network, strengthening of the pharmaceutical sales team and preparations for EU roll-out of the business.

Health Information is a pioneer in this field, and is launching first-to-market clinical messaging services within 40% of retail pharmacies and 50% of hospital pharmacies. Over the last three years Health Information has completed over 40 customer projects for 18 of the top 20 UK pharmaceutical companies.

Health Information’s mission is to enhance patients’ lives by enabling point of dispensing intervention. It has already supported millions of patients, and continues to pioneer new and innovative services, via its network of thousands of independent and hospital pharmacies.

Through its point of dispensing messaging, Health Information has repeatedly proven that it supports patients understanding of their conditions, improves compliance with their medication and drives strong growth of customer brands in a measurable fashion.

Mr Thomas Casdagli, from MVM, has joined the board. Mr Casdagli has over 9 years of healthcare investment experience and currently serves as a Member of the Boards of Alliance Pharma plc and Lombard Medical Technologies plc.

Mr Casdagli said, “We are delighted to be making this investment. Health Information’s position in the market and track record of ground-breaking, effective innovations, represent a unique opportunity. We are excited about the prospects for growth, both within the UK and continental Europe.”

Dr Grace Lomax, Founder of Health Information said “We are delighted to partner with a specialised healthcare investor like MVM to support the continuing growth of our business. MVM clearly recognise the value of clinical messaging in pharmacy and its ability to provide our partners with superior returns than traditional marketing and sales approaches.”

Patient Connect Limited

Patient Connect Limited
Pharmacy intervention

Downloads

DownloadFull Press Release

Latest News

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera

MVM Life Science Partners LLP closes MVM IV

MVM Life Science Partners LLP announces the closing of a $233 million healthcare fund, MVM IV.